JP-1302 (hydrochloride hydrate)

JP-1302 is an antagonist of α₂-adrenergic receptors (α₂-ARs) that is selective for α_2C-ARs over α_2A- and α_2B-ARs (K_is = 28, 3,150, and 1,470 nM, respectively). It reduces immobility time in the forced swim test in mice when administered at doses of 1, 3, and 10 μmol/kg. JP-1302 (5 mg/kg) reverses phencyclidine-induced decreases in prepulse inhibition of the acoustic startle response in rats. It dose-dependently reduces haloperidol-induced bradykinesia and catalepsy in mice. JP-1302 (0.3 mg/kg) also increases systolic blood pressure in rats.

[1] J SALLINEN. Pharmacological characterization and CNS effects of a novel highly selective α2C-adrenoceptor antagonist JP-1302[J]. British Journal of Pharmacology, 2009, 150 4: 391-402. DOI: 10.1038/sj.bjp.0707005
[2] JUNTA IMAKI. Therapeutic potential of α2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders[J]. Neuroscience Letters, 2009, 454 2: Pages 143-147. DOI: 10.1016/j.neulet.2009.03.001
[3] T L ZEFIROV. Effect of selective blockade of α-adrenoceptor subtypes on cardiovascular system in rats.[J]. Bulletin of Experimental Biology and Medicine, 2015, 158 4: 410-412. DOI: 10.1007/s10517-015-2774-3